Search Results
Jun 16, 2025, 10:48 ET Alliance Resource Partners, L.P. Announces 2025 Scholarship Recipients
graduate of North High School in Evansville, Indiana; daughter of John Hedges, employed by CR Services, LLC. Hyatt Kelley, graduate of Webster County High School in Dixon, Kentucky;
More news about: Alliance Resource Partners, L.P.
Jun 16, 2025, 09:00 ET AbelZeta Announces Promising Long-Term Outcomes for C-CAR039, a Novel CD19/CD20 Bi-Specific CAR-T Therapy, in Patients with R/R B NHL at EHA 2025
Key Findings: The overall response rate (ORR) and complete response (CR) rate were 91.5% and 85.1%, respectively for all patientsAmong the 43 LBCL pts, ORR and CR were 90.7% and 86.0%, respectivelyWith a median follow-up of 45.5 months (range, 3.1–62.8),
More news about: AbelZeta Pharma, Inc.
Jun 16, 2025, 09:00 ET AbbVie Provides Update on VERONA Trial for Newly Diagnosed Higher-Risk Myelodysplastic Syndromes
The primary outcome measure is overall survival (OS). Key secondary outcome measures include modified overall response (mOR) and complete remission (CR). More information can be found
More news about: AbbVie
Jun 16, 2025, 07:15 ET ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)
rate (ORR) of 84.6% (22/26); complete response (CR) rate of 69.2% (18/26)Among POD24 patients assessed for response, a CR rate of 61.5% (8/13) was observedCR was maintained in 17 of 18 CR patients who achieved CR, with longest duration of CR of 27 months from start of treatmentProgression-free
More news about: ADC Therapeutics SA
Jun 15, 2025, 10:17 ET INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen
the briefing document, the FDA stated: "[g]iven that [the ENVISION trial] lacked a concurrent control arm, the primary endpoints of complete response (CR) and duration of response (DOR) are difficult to interpret." The FDA also said it had "recommended a randomized trial design to the Applicant several
More news about: Faruqi & Faruqi, LLP
Jun 15, 2025, 03:15 ET Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
TECVAYLI®, providing the option for a reduced dosing frequency of 1.5 mg/kg every two weeks (Q2W) in patients who have achieved a complete response (CR) or better for a minimum of six months. TECVAYLI® is a first-in-class, bispecific T-cell engager antibody therapy that uses innovative science
More news about: Johnson & Johnson
Jun 13, 2025, 10:44 ET Prior to FIFA Club World Cup Kickoff, FC Mother and Omya Launch Landmark Joint Venture to Fund "Life Years" as Part of World Cup of Healing Legacy Project
Mexico Over the past 3 months, FC Mother has enrolled more than 210 expectant mothers in its program, which is now live with participants from CR Flamengo in Brazil, from San Diego FC in the US, and from Club Tigres in Mexico.
More news about: FC Mother
Jun 12, 2025, 17:46 ET 4 Emerging Graft versus Host Disease Therapies That Could Change the Treatment Landscape | DelveInsight
first-line aGVHD. While the study did not show a meaningful difference in CR or ORR at Day 29 versus placebo, itolizumab demonstrated statistically significant and clinically meaningful improvements in longer-term outcomes, including CR at Day 99, duration of response, and failure-free survival. In
More news about: DelveInsight Business Research, LLP
Jun 12, 2025, 16:02 ET BRIXMOR PROPERTY GROUP ISSUES ANNUAL CORPORATE RESPONSIBILITY REPORT
Corporate Responsibility (CR) Report, which provides a comprehensive overview of the Company's strategy to improve the environmental, social, and economic well-being of its stakeholders, as well as measurements and case studies that highlight Brixmor's progress with respect to its CR goals. "Our achievements
More news about: Brixmor Property Group Inc.
Jun 12, 2025, 11:00 ET New results for Johnson & Johnson's bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia
events and dose-limiting toxicity. Secondary efficacy measures included depletion of leukemic blasts, percentage of patients achieving complete response (CR), and percentage of patients who achieve overall response. About Bleximenib (JNJ-75276617) Bleximenib is an investigational oral
More news about: Johnson & Johnson
Jun 12, 2025, 10:13 ET CPSC Warns Consumers to Immediately Stop Using Sizhinai LED Tutu Skirts Due to Risk of Serious Injury or Death from Ingestion Hazard; Violations of Federal Standard for Consumer Products with Coin Batteries; Sold on Amazon.com by Hongkong Tianyu Electronic Commerce
skirts were sold in pink with silver circles and stars on the outer layer. The battery compartment of the lights connected to the skirts contains two CR2032 lithium coin batteries. CPSC is aware that the skirts were also sold in the colors light purple, purple, yellow, rose red, red, royal blue, light
More news about: U.S. Consumer Product Safety Commission
Jun 12, 2025, 06:30 ET ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress
by Lugano CriteriaComplete response (CR) rate of 86.7% (26/30 pts)Of these, 25/26 patients achieving CR remain in CR as of the data cut-offMedian time to CR in 120 µg/kg = 80 daysMedian time to CR in 150 µg/kg = 42 days
More news about: ADC Therapeutics SA
Jun 12, 2025, 06:13 ET Dizal Showcases Two First-in-Class Therapies in Hematologic Malignancies at EHA and ICML 2025
mechanism of action not only delivers strong anti-tumor activity—allowing 50% of patients with partial remission (PR) to achieve complete remission (CR)—but also modulates the tumor immune microenvironment through its anti-inflammatory and immunomodulatory effects. These unique features help delay relapse
More news about: Dizal Pharmaceutical
Jun 12, 2025, 03:00 ET Alghanim Industries, Starlink'in Çığır Açan Uydu İnternetini Küresel Pazarlara Taşıyor
content:https://www.prnewswire.com/news-releases/alghanim-industries-starlinkin-cr-acan-uydu-internetini-kuresel-pazarlara-tayor-302477827.html
More news about: Alghanim Industries
Jun 11, 2025, 11:40 ET URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
regarding UroGen's NDA for UGN-102, which stated that "[g]iven that ENVISION lacked a concurrent control arm, the primary endpoints of complete response (CR) and duration of response (DOR) are difficult to interpret," and that the FDA had "recommended a randomized trial design to the Applicant several times
More news about: Robbins Geller Rudman & Dowd LLP
Jun 11, 2025, 09:43 ET Canada Nickel Announces Initial Resource at Mann West Nickel Sulphide Project
Fe(%) Cr(%) Pd(g/t)
More news about: Canada Nickel Company Inc.
Jun 11, 2025, 08:30 ET TC BioPharm Announces Complete Response in Minimal Residual Disease (MRD) Patient
First patient in Cohort B achieved CR after 2nd dose of TCB008EDINBURGH, Scotland, June 11, 2025 /PRNewswire/ --
More news about: TC BioPharm
Jun 11, 2025, 06:00 ET Sixth Digital Collectibles by Cristiano Ronaldo and Binance Will Take Fans To Meet CR7
June 27, 2025, or until fully redeemed – there are only 7,777 in total up for grabs. Holders of all CR7 collectibles (Drops 1 to 5) will receive 5 mystery boxes each. Holders of at least one CR7 collectible from any collection can get mystery boxes by participating in activities in the closed holder-only
More news about: Binance
Jun 10, 2025, 11:00 ET Hudini launches digital check-in solution for Pestana Hotel Group in 30+ hotels across Portugal
Owning and managing 100+ hotels in 16 countries, with a total of 12,000 keys and 3.5 million guests every year, Pestana began its roll-out at the Pestana CR7 Lisbon hotel. With Staff Connect, it is expected that the Pestana Hotels will reduce check-in times by as much as 50%.
More news about: Hudini
Jun 10, 2025, 10:17 ET DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen
the briefing document, the FDA stated: "[g]iven that [the ENVISION trial] lacked a concurrent control arm, the primary endpoints of complete response (CR) and duration of response (DOR) are difficult to interpret." The FDA also said it had "recommended a randomized trial design to the Applicant several
More news about: Faruqi & Faruqi, LLP
Jun 09, 2025, 10:35 ET Show de Cidade Negra no João Rock terá participação de membros do Playing For Change
https://mma.prnewswire.com/media/2706343/Mermans_Mosengo___Cr_dito__Divulga__o.jpg
More news about: João Rock
Jun 06, 2025, 21:35 ET URGN INVESTOR DEADLINE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
regarding UroGen's NDA for UGN-102, which stated that "[g]iven that ENVISION lacked a concurrent control arm, the primary endpoints of complete response (CR) and duration of response (DOR) are difficult to interpret," and that the FDA had "recommended a randomized trial design to the Applicant several times
More news about: Robbins Geller Rudman & Dowd LLP
Jun 05, 2025, 13:30 ET UroGen Pharma Ltd. (URGN) Faces Securities Class Action Amid FDA's Briefing Document and Subsequent ODAC Vote Against UGN-102- Hagens Berman
efficacy and safety. In addition, ODAC was advised "[g]iven that ENVISION lacked a concurrent control arm, the primary endpoints of complete response (CR) and duration of response (DOR) are difficult to interpret." Ultimately, on May 21, 2025, UroGen announced that
More news about: Hagens Berman Sobol Shapiro LLP
Jun 05, 2025, 10:00 ET Highlights in Oral Presentation of Mabwell's 9MW2821 at 2025 ASCO
Objective Response Rate (ORR) was 87.5% (95% CI: 73.2, 95.8), confirmed ORR was 80%, complete response (CR) rate was 12.5%, Disease Control Rate (DCR) was 92.5% (95% CI: 79.6, 98.4). 97.5% of assessable patients had tumor
More news about: Mabwell
Jun 04, 2025, 11:25 ET INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen
the briefing document, the FDA stated: "[g]iven that [the ENVISION trial] lacked a concurrent control arm, the primary endpoints of complete response (CR) and duration of response (DOR) are difficult to interpret." The FDA also said it had "recommended a randomized trial design to the Applicant several
More news about: Faruqi & Faruqi, LLP